Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Hereditary cancer predisposition due to variation(s) in the ATM gene. Pathogenic germline variation in ATM confers an autosomal dominant predisposition to tumor formation at multiple primary sites, including breast cancer, ovarian cancer, pancreatic cancer, and prostate cancer.
Biomarker and diagnostic research for ATM-related cancer predisposition has been reported in the published literature.
No clinical trials have been registered for ATM-related cancer predisposition.
3 publications have been identified in PubMed for ATM-related cancer predisposition. Research spans Diagnostic / Biomarker (33%), Case Report / Case Series (33%), and Basic Science / Preclinical (33%).
Palleschi M (2025). [PMID: 40338220](https://pubmed.ncbi.nlm.nih.gov/40338220/). *Oncologist*. [Basic Science / Preclinical]
Bondavalli D (2025). [PMID: 39663696](https://pubmed.ncbi.nlm.nih.gov/39663696/). *Tumori*. [Case Report / Case Series]
Glennon KI (2024). [PMID: 39088769](https://pubmed.ncbi.nlm.nih.gov/39088769/). *JCO Precis Oncol*. [Diagnostic / Biomarker]
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 12:30 PM UTC
Common questions about ATM-related cancer predisposition